MA44037B1 - Modulateurs du récepteur adrénergique bêta 3 utile dans le traitement ou la prévention de troubles associés à ceux-ci - Google Patents

Modulateurs du récepteur adrénergique bêta 3 utile dans le traitement ou la prévention de troubles associés à ceux-ci

Info

Publication number
MA44037B1
MA44037B1 MA44037A MA44037A MA44037B1 MA 44037 B1 MA44037 B1 MA 44037B1 MA 44037 A MA44037 A MA 44037A MA 44037 A MA44037 A MA 44037A MA 44037 B1 MA44037 B1 MA 44037B1
Authority
MA
Morocco
Prior art keywords
beta
treatment
prevention
adrenergic receptor
associated therewith
Prior art date
Application number
MA44037A
Other languages
English (en)
Other versions
MA44037A1 (fr
Inventor
Thuy-Anh Tran
Quyen-Quyen Do
Brett Ullman
c blackburn Anthony
Nagura Maiko
Original Assignee
Arena Pharm Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Arena Pharm Inc filed Critical Arena Pharm Inc
Publication of MA44037A1 publication Critical patent/MA44037A1/fr
Publication of MA44037B1 publication Critical patent/MA44037B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/10—Spiro-condensed systems
    • C07D491/107—Spiro-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/438—The ring being spiro-condensed with carbocyclic or heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5383—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4525—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with oxygen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Peptides Or Proteins (AREA)

Abstract

Cette invention concerne certains composés de formule (ia) et leurs compositions pharmaceutiques qui modulent l'activité du récepteur adrénergique bêta 3. Des composés de la présente invention et leurs compositions pharmaceutiques ciblent des procédés utiles dans le traitement d'un trouble médié par le récepteur adrénergique bêta 3, tel que l'insuffisance cardiaque, l'activité cardiaque dans l'insuffisance cardiaque, la mortalité, la récidive d'infarctus et/ou l'hospitalisation en relation avec l'insuffis
MA44037A 2016-06-06 2017-06-04 Modulateurs du récepteur adrénergique bêta 3 utile dans le traitement ou la prévention de troubles associés à ceux-ci MA44037B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662346293P 2016-06-06 2016-06-06
PCT/US2017/035867 WO2017214002A1 (fr) 2016-06-06 2017-06-05 Modulateurs du récepteur adrénergique bêta 3 utile dans le traitement ou la prévention de troubles associés à ceux-ci

Publications (2)

Publication Number Publication Date
MA44037A1 MA44037A1 (fr) 2019-05-31
MA44037B1 true MA44037B1 (fr) 2020-03-31

Family

ID=59067920

Family Applications (2)

Application Number Title Priority Date Filing Date
MA44037A MA44037B1 (fr) 2016-06-06 2017-06-04 Modulateurs du récepteur adrénergique bêta 3 utile dans le traitement ou la prévention de troubles associés à ceux-ci
MA045150A MA45150A (fr) 2016-06-06 2017-06-05 Modulateurs du récepteur adrénergique-bêta-3 utiles pour le traitement et la prevention de troubles associes a ce dernier

Family Applications After (1)

Application Number Title Priority Date Filing Date
MA045150A MA45150A (fr) 2016-06-06 2017-06-05 Modulateurs du récepteur adrénergique-bêta-3 utiles pour le traitement et la prevention de troubles associes a ce dernier

Country Status (29)

Country Link
US (5) US20190284200A1 (fr)
EP (1) EP3464292B8 (fr)
JP (3) JP6771246B2 (fr)
KR (2) KR102408272B1 (fr)
CN (1) CN109563103B (fr)
AR (1) AR108772A1 (fr)
AU (2) AU2017278102B2 (fr)
CA (1) CA3026024C (fr)
CL (1) CL2018003451A1 (fr)
CO (1) CO2019000041A2 (fr)
CR (1) CR20180595A (fr)
DK (1) DK3464292T3 (fr)
EA (1) EA201892817A1 (fr)
EC (1) ECSP19001018A (fr)
ES (1) ES2929737T3 (fr)
IL (2) IL289378B (fr)
MA (2) MA44037B1 (fr)
MX (2) MX387995B (fr)
MY (1) MY195982A (fr)
NI (1) NI201800130A (fr)
NZ (1) NZ749202A (fr)
PE (1) PE20190445A1 (fr)
PH (1) PH12018502550B1 (fr)
PT (1) PT3464292T (fr)
SG (1) SG11201810788QA (fr)
TN (1) TN2018000391A1 (fr)
TW (2) TWI784840B (fr)
UA (1) UA125120C2 (fr)
WO (1) WO2017214002A1 (fr)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MA44037B1 (fr) * 2016-06-06 2020-03-31 Arena Pharm Inc Modulateurs du récepteur adrénergique bêta 3 utile dans le traitement ou la prévention de troubles associés à ceux-ci
JP6594570B2 (ja) 2017-03-20 2019-10-23 フォーマ セラピューティクス，インコーポレイテッド ピルビン酸キナーゼ（ｐｋｒ）活性化剤としてのピロロピロール組成物
AR114156A1 (es) * 2017-12-06 2020-07-29 Arena Pharm Inc MODULADORES DEL RECEPTOR ADRENÉRGICO b-3 ÚTILES PARA EL TRATAMIENTO O LA PREVENCIÓN DE TRASTORNOS RELACIONADOS CON ESTE
WO2020061378A1 (fr) 2018-09-19 2020-03-26 Forma Therapeutics, Inc. Traitement de la drépanocytose avec un composé activant la pyruvate kinase r
WO2020061255A1 (fr) 2018-09-19 2020-03-26 Forma Therapeutics, Inc. Activation de la pyruvate kinase r
AU2020350763A1 (en) 2019-09-19 2022-04-07 Novo Nordisk Health Care Ag Pyruvate kinase R (PKR) activating compositions
US12128035B2 (en) 2021-03-19 2024-10-29 Novo Nordisk Health Care Ag Activating pyruvate kinase R
WO2023017388A1 (fr) * 2021-08-09 2023-02-16 Arena Pharmaceuticals, Inc. Modulateurs du récepteur bêta-3 adrénergique utiles dans le traitement ou la prévention de l'insuffisance cardiaque
EP4392032A1 (fr) * 2021-08-26 2024-07-03 Arena Pharmaceuticals, Inc. Modulateurs du récepteur bêta-3 adrénergique pour le traitement ou la prévention de la maladie kystique rénale et du syndrome cardio-rénal
US20240409548A1 (en) * 2021-10-06 2024-12-12 Arena Pharmaceuticals, Inc. Modulators of the beta-3 adrenergic receptor useful for the treatment or prevention of disorders related thereto
JP2025506667A (ja) * 2022-02-14 2025-03-13 バイオジェン・エムエイ・インコーポレイテッド エモパミル結合タンパク質阻害剤及びその使用
CN114539103B (zh) * 2022-03-21 2023-04-07 佳木斯黑龙农药有限公司 2-二氟乙氧基-6-三氟甲基苯磺酰氯的合成方法
CN116178220A (zh) * 2022-12-13 2023-05-30 爱斯特（成都）生物制药股份有限公司 一种制备(2s)-2-[[3-(甲基磺酰基l)苯氧基]甲基]环氧乙烷的方法

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3028340C2 (de) * 1980-07-25 1987-02-05 Dr. Willmar Schwabe GmbH & Co, 7500 Karlsruhe Amino-desoxy-1.4;3.6-dianhydro-hexit-nitrate, Verfahren zu ihrer Herstellung und diese Verbindungen enthaltende pharmazeutische Zubereitungen
US5254595A (en) 1988-12-23 1993-10-19 Elf Sanofi Aryloxypropanolaminotetralins, a process for their preparation and pharmaceutical compositions containing them
FR2751646B1 (fr) 1996-07-23 1999-01-22 Sanofi Sa Phenoxypropanolamine a action antagoniste beta3-adrenergique
AU7738298A (en) 1996-12-19 1998-07-15 Agrevo Uk Limited Chromones useful as fungicides
FR2780057B1 (fr) * 1998-06-18 2002-09-13 Sanofi Sa Phenoxypropanolamines, procede pour leur preparation et compositions pharmaceutiques les contenant
DE60033964T2 (de) * 1999-12-17 2007-11-29 Sanofi-Aventis Phenoxypropanolamin-derivate, ihre herstellung und therapeutische verwendung
DE20204129U1 (de) 2002-03-15 2002-07-25 Wella Ag, 64295 Darmstadt Mittel zur Färbung von Keratinfasern mit Chinolinium-Farbstoffen
WO2005092860A1 (fr) * 2004-03-23 2005-10-06 Pfizer Limited Composes servant au traitement de maladies
WO2006060122A2 (fr) * 2004-11-30 2006-06-08 Artesian Therapeutics, Inc. Composes cardiotoniques dotes d'une activite inhibitrice dirigee contre les recepteurs beta-adrenergiques et la phosphodiesterase
US8697674B2 (en) 2004-12-29 2014-04-15 Naturon, Inc. Xanthurenic acid derivative pharmaceutical compositions and methods related thereto
WO2008094507A2 (fr) 2007-01-26 2008-08-07 Cellicon Biotechnologies, Inc. Nouveaux composés de fusion
US8039505B2 (en) 2007-04-11 2011-10-18 University Of Utah Research Foundation Compounds for modulating T-cells
US8722851B2 (en) 2007-11-02 2014-05-13 Pain Therapeutics, Inc. Analgesia with minimal tolerance and dependence by a mu opioid receptor agonist that also binds filamin A
US20100279997A1 (en) 2009-05-04 2010-11-04 Lindsay Burns Barbier Analgesic that binds filamin a
CA2779252C (fr) 2008-10-31 2015-05-05 Pain Therapeutics, Inc. Analgesique anti-inflammatoire se liant a la filamine a
CA2779261C (fr) 2008-10-31 2015-03-24 Pain Therapeutics, Inc. Anti-inflammatoire et analgesique se liant a la filamine a
CA2741839A1 (fr) * 2008-11-21 2010-05-27 Pfizer Inc. 1-oxa-8-azaspiro[4.5]decane-8-carboxamides en tant qu'inhibiteurs de faah
WO2011137024A1 (fr) * 2010-04-26 2011-11-03 Merck Sharp & Dohme Corp. Nouveaux inhibiteurs de spiropipéridine prolylcarboxypeptidase
CN103140134B (zh) * 2010-07-23 2015-07-29 默沙东公司 新吡咯烷衍生的β3肾上腺素能受体激动剂
JP2012092038A (ja) 2010-10-26 2012-05-17 F Hoffmann La Roche Ag 糖尿病、糖尿病関連疾患又は糖尿病性合併症の予防又は治療剤
WO2014011917A2 (fr) 2012-07-13 2014-01-16 Pain Therapeutics, Inc. Méthode pour inhiber la phosphorylation de la protéine tau
EP2872899B1 (fr) 2012-07-13 2018-07-11 Pain Therapeutics, Inc. Analyse de la maladie d'alzheimer chez un patient vivant
GB201405359D0 (en) 2014-03-25 2014-05-07 Univ Liverpool Synthetic process
MA44037B1 (fr) 2016-06-06 2020-03-31 Arena Pharm Inc Modulateurs du récepteur adrénergique bêta 3 utile dans le traitement ou la prévention de troubles associés à ceux-ci
AR114156A1 (es) * 2017-12-06 2020-07-29 Arena Pharm Inc MODULADORES DEL RECEPTOR ADRENÉRGICO b-3 ÚTILES PARA EL TRATAMIENTO O LA PREVENCIÓN DE TRASTORNOS RELACIONADOS CON ESTE

Also Published As

Publication number Publication date
IL289378B (en) 2022-09-01
UA125120C2 (uk) 2022-01-12
PH12018502550A1 (en) 2019-11-04
US11560386B2 (en) 2023-01-24
EP3464292A1 (fr) 2019-04-10
AU2017278102A1 (en) 2019-01-17
AU2021206809B2 (en) 2023-01-05
JP6771246B2 (ja) 2020-10-21
CA3026024A1 (fr) 2017-12-14
IL263148A (en) 2018-12-31
US10927123B2 (en) 2021-02-23
TW201803877A (zh) 2018-02-01
JP2020203945A (ja) 2020-12-24
JP7449329B2 (ja) 2024-03-13
EP3464292B1 (fr) 2022-09-21
ES2929737T3 (es) 2022-12-01
US10662200B2 (en) 2020-05-26
JP7083087B2 (ja) 2022-06-10
ECSP19001018A (es) 2019-02-28
CO2019000041A2 (es) 2019-04-30
US20210340154A1 (en) 2021-11-04
EA201892817A1 (ru) 2019-06-28
NZ749202A (en) 2022-07-01
WO2017214002A1 (fr) 2017-12-14
JP2022089984A (ja) 2022-06-16
IL289378A (en) 2022-02-01
SG11201810788QA (en) 2018-12-28
PE20190445A1 (es) 2019-03-29
CL2018003451A1 (es) 2019-02-22
MX2018015124A (es) 2019-09-09
US20190389875A1 (en) 2019-12-26
MY195982A (en) 2023-02-27
TW202237619A (zh) 2022-10-01
JP2019518079A (ja) 2019-06-27
TWI784840B (zh) 2022-11-21
PT3464292T (pt) 2022-11-15
KR20190026731A (ko) 2019-03-13
MA45150A (fr) 2021-05-05
TWI752963B (zh) 2022-01-21
AU2017278102B2 (en) 2021-04-29
US20190292196A1 (en) 2019-09-26
BR112018075201A2 (pt) 2019-03-19
CA3026024C (fr) 2024-07-02
US20200270264A1 (en) 2020-08-27
EP3464292B8 (fr) 2022-10-26
US20190284200A1 (en) 2019-09-19
IL263148B (en) 2022-02-01
MA44037A1 (fr) 2019-05-31
KR20220025128A (ko) 2022-03-03
MX2021014043A (es) 2022-02-21
TN2018000391A1 (en) 2020-06-15
CR20180595A (es) 2019-04-09
CN109563103B (zh) 2022-05-27
MX387995B (es) 2025-03-19
AR108772A1 (es) 2018-09-26
NI201800130A (es) 2019-06-13
KR102408272B1 (ko) 2022-06-10
AU2021206809A1 (en) 2021-08-12
DK3464292T3 (da) 2022-10-31
US10479797B2 (en) 2019-11-19
CN109563103A (zh) 2019-04-02
PH12018502550B1 (en) 2023-01-27

Similar Documents

Publication Publication Date Title
MA44037B1 (fr) Modulateurs du récepteur adrénergique bêta 3 utile dans le traitement ou la prévention de troubles associés à ceux-ci
MA43131B1 (fr) Compositions et procédés d'inhibition de l'activité de l'arginase
MA57412B1 (fr) Benzopyrrole substitués et inhibiteurs du complément structurellement apparentés
MA40290A1 (fr) Agents immunorégulateurs
MA52948B1 (fr) Composés
MA51620B1 (fr) Analogues de dihydrobenzofurane et d'inden en tant qu'inhibiteurs de sarcomes cardiaques
MA45985B1 (fr) Inhibiteurs de diacylglycérol acyltransférase 2
MA41562A1 (fr) Agonistes d'apj 4-hydroxy-3-(heteroaryl)pyridine-2-one a utiliser dans le traitement de troubles cardio-vasculaires
MA34474B1 (fr) Agonistes de gpr40
MA35460B1 (fr) Composés et compositions en tant qu'inhibiteurs de kinase c-kit
MA39783A (fr) Dérivés de quinoxaline utiles en tant que modulateurs de la fgfr kinase
MA43409B1 (fr) Composés polycycliques à utiliser en tant qu'inhibiteurs de la tyrosine kinase de bruton
MA34361B1 (fr) Dérivés de tétrahydro-pyrido-pyrimidine
MA39753B1 (fr) Inhibiteurs de diacylglycérol acyltransférase pour le traitement de troubles métaboliques ou analogues
MA39219A1 (fr) Nouveaux composés inhibiteurs de la kinase lrrk2 utilisés pour le traitement du parkinson, de l’alzheimer et de la sclérose latérale amyotrophique
MA54386B1 (fr) Modulateurs de trex1
MA46101A (fr) Modulateurs allostériques positifs du récepteur muscarinique m1
MA38810B1 (fr) Inhibiteurs de rorc2 méthodes d'utilisation associées
CY1125348T1 (el) Νεοι ανταγωνιστες υποδοχεων β2 βραδυκινινης
MA58049B1 (fr) Antagonistes du récepteur du sous-type 2 de la mélanocortine (mc2r) à pipéridine à double substitution gem et leurs utilisations
MX2022003365A (es) Anticuerpos de un solo dominio dirigidos contra lilrb2.
MA39335A1 (fr) Inhibiteurs mgat2 de dihydropyridinone à substitution tétrazolone
EA202190272A1 (ru) Дополнительно замещенные производные триазолохиноксалина
MA43052B1 (fr) Inhibiteurs de la kallicréine plasmatique humaine
EA202190271A1 (ru) Замещенные триазолохиноксалиновые производные